Multicenter Trial for Adults With Partial Seizures

Efficacy and Safety of Talampanel as Adjunctive Therapy in Patients With Partial Seizures: A Phase II Clinical Trial.

To compare seizure frequency in patients with refactory partial seizures (with or without generalization) who are taking Talampanel versus placebo as an add-on therapy to other licensed concomitant antiepileptic drugs (AEDs) and to determine the safety of Talampanel in this group of patients.

A randomized, double-blind, placebo controlled, multicenter, efficacy and safety study of talampanel (TLP) in 190 patients (18-65 years old) with refractory partial seizures.

Inclusion Criteria:

• must weigh greater than or equal to 40kg
• Patients must have diagnosis of partial seizures
• At least 3 observable partial seizures a month
• Are currently being treated with 1 and no more than 2 marketed Anti-epileptic Drugs.

Exclusion:

• Patients on Valproic acid, and Felbamate